
News|Articles|December 1, 2001
FDA Actions in Brief
A once-daily, extended-release form of the amphetamine and dextroamphetamine mixture Adderall (Adderall XR, Shire) has been approved for treatment of attention-deficit/hyperactivity disorder. The new product is supplied in capsules that provide double-pulsed amphetamine delivery, prolonging the amphetamine release compared with immediate-release Adderall.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Judi Health, Employers Health team up to launch new PBM solution
2
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
3
Brandon Kessler on pharmacy pricing under CAA 2026 | PBMI 2026
4
Brandon Kessler on advice to employers about meeting their fiduciary responsibility | PBMI 2026
5
























